ARS Pharmaceuticals (SPRY) said Friday it has signed an agreement with allergy immunotherapy firm ALK-Abello to co-promote Neffy nasal spray to up to 9,000 pediatricians in the US.
Under the four-year deal, ARS will recognize all US revenue and will continue to have sole responsibility for all US commercialization activities, ARS said.
ARS said it expects its operating expense outlook for 2025 to rise by about $3 million per quarter starting in Q3 under the deal but said its 2025 cash flow won't be impacted.
The agreement follows a licensing deal between ARS and ALK-Abello, which provided ARS with $145 million upfront and gave ALK commercialization rights to Neffy in Canada, the UK, the EU and other countries outside the US, ARS said.
Shares of ARS Pharmaceuticals were 3.5% higher in recent trading.
Price: 14.55, Change: +0.39, Percent Change: +2.72
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。